SCHEMBL977852

SCHEMBL977852

O[C@@H]1[C@@H](OCc2ccccc2)O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.54
GJB2 P29033 1/20 0.53
PTPN1 P18031 9/20 0.51
CDC25B P30305 8/20 0.51
PTPN2 P17706 5/20 0.51
PTPN11 Q06124 5/20 0.51
PTPN6 P29350 4/20 0.51
SSTR1 P30872 1/20 0.50
SSTR2 P30874 1/20 0.50
SSTR4 P31391 1/20 0.50
SSTR3 P32745 1/20 0.50
SSTR5 P35346 1/20 0.50
HTR1A P08908 1/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
SLC6A2 P23975 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10523689 1.00 NT5E (0.54) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL8221413 1.00 NT5E (0.54) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL18744555 1.00 NT5E (0.54) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL10523693 1.00 NT5E (0.54) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL14414817 0.96 GJB2 (0.56) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL5466098 0.96 GJB2 (0.56) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL4928707 0.93 GJB2 (0.57) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL4909410 0.93 GJB2 (0.57) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL7149647 0.92 TACR2 (0.51) NT5EGJB2PTPN1CDC25BPTPN2
SCHEMBL7148237 0.92 TACR2 (0.51) NT5EGJB2PTPN1CDC25BPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720889-B1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LTD (AU) 2014-11-26 EP disclosed
US-8173606-B2 Sulfated oligosaccharide derivatives PROGEN PHARMACEUTICALS LIMITED (AU) 2012-05-08 US disclosed
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LIMITED (AU) 2011-06-02 US disclosed
US-7875592-B2 inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease PROGEN PHARMACEUTICALS LIMITED (AU) 2011-01-25 US disclosed
EP-1720889-A4 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LTD (AU) 2008-03-19 EP disclosed
US-20070185037-A1 Sulfated oligosaccharide derivatives PROGEN INDUSTRIES LIMITED (AU) 2007-08-09 US disclosed
EP-1720889-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES Progen Industries Limited (AU) 2006-11-15 EP disclosed
WO-2005085264-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN INDUSTRIES LIMITED (AU) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185037-A1 Sulfated oligosaccharide derivatives HPSE, APOB, LIPG NT5E 1735/4885GJB2 4864/4885PTPN1 612/4885
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES HPSE, APOB, LIPG NT5E 1735/4885GJB2 4864/4885PTPN1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.